Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

[1]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. , 2019 .

[2]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[3]  N. Dawson,et al.  Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. , 2017, Journal of managed care & specialty pharmacy.

[4]  K. Brasso,et al.  A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. , 2016, Urologic oncology.

[5]  H. Sze,et al.  Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience , 2016, BMC Urology.

[6]  B. Escudier,et al.  Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. , 2015, European journal of cancer.

[7]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[9]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.